• Publications
  • Influence
Acute coronary syndrome: What is the cost-effectiveness of prevention, point-of-care technology and telemonitoring?
TLDR
A cost-analysis that calculates the impact of three interventions for patients identified as ‘at risk’ for Acute Coronary Syndrome - a cardio-vascular exercise programme, point-of-care digital diagnostics, and telemonitoring adherence tools finds the largest impact is measured when all three interventions are utilized simultaneously.
WHO issues another gloomy tuberculosis report
  • N. Moran
  • Medicine
    Nature Medicine
  • 1 April 1996
Boehringer splashes out on bispecific antibody platforms
  • N. Moran
  • Biology, Medicine
    Nature Biotechnology
  • 1 January 2011
TLDR
F-star’s deal with the Ingleheimbased pharma requires the startup to run seven targets through its modular antibody technology platform, which allows the introduction of additional antigen-binding sites into mAbs and mAb fragments by engineering the loops of Fc and Fv domains outside of complementaritydetermining regions (CDRs).
p38 kinase inhibitor approved for idiopathic pulmonary fibrosis
  • N. Moran
  • Medicine, Biology
    Nature Biotechnology
  • 1 April 2011
First gene therapy nears landmark European market authorization
  • N. Moran
  • Medicine, Biology
    Nature Biotechnology
  • 10 September 2012
TLDR
UniQure’s investment in regulatory work has parallels with the amount of time and effort the FDA and other agencies put into establishing the safety of monoclonal antibodies (mAbs) and biopharmaceuticals, says co-founder Sander van Deventer.
Shire's replacement enzymes validate gene activation
  • N. Moran
  • Biology, Medicine
    Nature Biotechnology
  • 5 November 2010
TLDR
Genzyme’s manufacturing strife and the urgent search for alternatives to meet patients’ needs have propelled Shire and its gene-activation technology to the fore.
First gene therapy approved
  • N. Moran
  • Biology
    Nature Biotechnology
  • 7 December 2012
TLDR
The European Commission granted marketing authorization for Glybera (alipogene tiparvovec) for the treatment of the ultra-rare inherited disorder, lipoprotein lipase (LPL) deficiency, on November 2, marking the beginning of a significant growth path for gene therapy.
Fractured European market undermines biosimilar launches
  • N. Moran
  • Medicine, Biology
    Nature Biotechnology
  • 2008
TLDR
This year will see the first serious engagements in the biogenerics war, as two copycat versions of the world’s biggest-selling biotech drug, erythropoietin (EPO), hit the market in Europe, and the biosimilars market is fractioning before the first products are even established.
Incyte comes of age with JAK inhibitor approval
  • N. Moran
  • Biology, Medicine
    Nature Biotechnology
  • 9 January 2012
TLDR
Jakafi’s approval in myeloproliferative disorders lights the way for small-molecule JAK inhibitors under development for other indications, in particular solid cancers and inflammatory diseases.
European court bans embryonic stem cell patents
  • N. Moran
  • Biology, Medicine
    Nature Biotechnology
  • 8 December 2011
TLDR
Researchers are shocked by the implication that their research is immoral, concerned that research funding could be threatened and commercialization of ESCderived cell therapy hindered in Europe, and views remain mixed, however, on the likely impact of the ruling on commercialization.
...
1
2
3
4
5
...